Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Ophthalmology

The Biology of Scleral Melting and Systemic Disease

At a Glance

Scleromalacia perforans is severe, often painless thinning of the eye’s sclera that is most strongly linked to longstanding rheumatoid arthritis and can signal other immune disease. Doctors must rule out infection because immune-suppressing and antimicrobial treatments are opposite.

Scleromalacia perforans (SP) is more than just an eye condition; it is a visible sign of an internal immune process. While most eye problems are localized, SP is typically a “window” into how your immune system is behaving throughout your entire body. Understanding why the eye wall “melts” requires looking at the biology of collagen and the way your immune system communicates [1][2].

The Biology of Scleral Thinning

The white of your eye (the sclera) is made primarily of collagen, the same tough protein that provides structure to your skin, tendons, and joints [3]. Scleritis and scleral necrosis involve complex, incompletely defined immune-mediated and ischemic (lack of blood flow) mechanisms, and not every case has the same pathway.

Researchers believe several mechanisms may contribute to this tissue loss:

  • Immune Complex Deposition: Your body produces proteins called antibodies to fight germs. In autoimmune disease, these antibodies can bind to “self” proteins, forming clumps called immune complexes. When these clumps settle in the small blood vessels of the eye, they may trigger a localized attack [4][5].
  • Vascular Starvation: This immune attack may damage the tiny blood vessels that nourish the sclera. Because the sclera already has a limited blood supply, this damage leads to ischemia (a lack of oxygen and nutrients). Without blood, the tissue begins to die—a process called avascular necrosis [1][6].
  • Enzymatic Breakdown: As the tissue breaks down, cells release powerful enzymes called matrix metalloproteinases (MMPs) or “collagenases.” However, there is no routine approved treatment that directly targets MMPs; instead, treatments address the immune response [4][3].

The Rheumatoid Arthritis Connection

The strongest link to scleromalacia perforans is Rheumatoid Arthritis (RA) [7]. While only a small percentage of people with RA will ever develop this eye condition, those who do typically have had RA for a long time—often 20 years or more [8][9].

In these cases, the disease has moved beyond the joints and is affecting other connective tissues. Occasionally, SP can be the very first sign of RA, appearing before you ever feel a “twinge” in your hands or knees [10][9].

Other Systemic Links: ANCA and Vasculitis

Scleromalacia perforans is also associated with a group of conditions called ANCA-associated vasculitis, such as Granulomatosis with Polyangiitis (GPA) [7][11]. These are rare diseases that cause inflammation of the blood vessels.

If you have SP, your doctors may test for ANCA antibodies. Finding these antibodies does not mean your lungs or kidneys are already involved, but it does prompt systemic assessment. Testing and organ evaluation should be guided by the clinical picture, and a positive ANCA prompts your doctor to investigate further [12][11].

The Critical Distinction: Autoimmune vs. Infectious

It is vital for your care team to determine if the “melting” is caused by your immune system (autoimmune) or by a germ (infectious). While they can look very similar, the treatments are opposite:

  • Autoimmune Scleritis: Treated by suppressing the immune system with steroids or specialized biologics to stop the attack on the eye [13][14].
  • Infectious Scleritis: Usually caused by bacteria like Pseudomonas or fungi, often following an old eye surgery or injury [14][15]. This is treated with aggressive antibiotics or antifungals.

Using immune-suppressing drugs on an undiagnosed infection can be dangerous. Your care team cannot tell the difference just by looking at a scan like AS-OCT. The distinction is made through medical history, clinical examination, response to treatment, and—when indicated—cultures or tissue sampling [6][14].

Common questions in this guide

Why does the sclera melt in scleromalacia perforans?
Scleromalacia perforans can involve an immune attack on the small blood vessels that nourish the sclera. Reduced blood flow can deprive the tissue of oxygen, while enzymes called collagenases break down collagen; the exact combination of mechanisms varies from person to person.
How is scleromalacia perforans related to rheumatoid arthritis?
Rheumatoid arthritis is the strongest systemic association, especially when it has been present for many years and affects tissues beyond the joints. In some people, the eye changes appear before joint symptoms, so an ophthalmologist may recommend evaluation by a rheumatologist.
Does scleromalacia perforans mean I have vasculitis?
Not necessarily. Scleromalacia perforans can occur with ANCA-associated vasculitis, including granulomatosis with polyangiitis, but a positive ANCA blood test does not by itself prove that the lungs or kidneys are involved. Doctors use your symptoms, examination, and other tests to decide whether further organ evaluation is needed.
How can doctors tell autoimmune scleral melting from an infection?
Autoimmune and infectious scleral inflammation can look alike, so doctors consider your history, examination, and response to treatment and may obtain cultures or a tissue sample when needed. Autoimmune disease is treated by calming the immune system, whereas infection requires antibiotics or antifungal medicine; immunosuppressive treatment can be dangerous if an infection has not been recognized.
Can scleromalacia perforans be painless?
It can cause little or no pain, so the absence of discomfort does not reliably show that the condition is inactive. Regular eye examinations and the monitoring plan set by your eye specialist are important when scleral thinning is present.
Are there medicines that directly stop collagen-destroying enzymes in scleromalacia perforans?
There is no routine approved treatment that directly targets matrix metalloproteinases, the enzymes that can break down collagen. Treatment generally focuses on controlling the underlying immune response, or on treating an infection when infection is the cause.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given the connection between my eye and my immune system, should we re-evaluate my rheumatoid arthritis management?
  2. 2.Was a culture or molecular test performed to definitively rule out an infection before starting my current treatment?
  3. 3.Do I need to be screened for ANCA-associated vasculitis (GPA) or other systemic conditions I might not be aware of?
  4. 4.How does the lack of pain in my case change how we monitor for 'melting' compared to someone with painful scleritis?
  5. 5.Are we using treatments that specifically target the collagen-destroying enzymes (like MMPs) in my eye?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    [Diagnosis and treatment approach for necrotizing scleritis (NS): A clinical case].

    Hernández-Camarena JC, Rodríguez-García A, Valdez-García J

    Gaceta medica de Mexico 2015; (151(4)):525-8.

    PMID: 26290030
  2. 2

    [Scleritis and systemic diseases: What should know the internist?]

    Bielefeld P, Saadoun D, Héron E, et al.

    La Revue de medecine interne 2018; (39(9)):711-720 doi:10.1016/j.revmed.2018.02.001.

    PMID: 29496270
  3. 3

    Potential Biomarkers for Noninfectious Scleritis Identified by Serum and Tear Fluid Proteomics.

    Vergouwen DPC, Kolijn PM, de Hoog J, et al.

    Ophthalmology science 2024; (4(1)):100407 doi:10.1016/j.xops.2023.100407.

    PMID: 38054106
  4. 4

    The clinical and pathogenic spectrum of surgically-induced scleral necrosis: A review.

    Ruiz-Lozano RE, Garza-Garza LA, Davila-Cavazos O, et al.

    Survey of ophthalmology 2021; (66(4)):594-611 doi:10.1016/j.survophthal.2020.12.008.

    PMID: 33422510
  5. 5

    Current Approach for the Diagnosis and Management of Noninfective Scleritis.

    Dutta Majumder P, Agrawal R, McCluskey P, Biswas J

    Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2020; (10(2)):212-223 doi:10.1097/APO.0000000000000341.

    PMID: 33290287
  6. 6

    Monitoring therapy in anterior necrotizing scleritis with inflammation with anterior segment optical coherence tomography.

    Vidal Oliver L, López Montero A, Gil Hernández I, et al.

    European journal of ophthalmology 2021; 11206721211065564 doi:10.1177/11206721211065564.

    PMID: 34866457
  7. 7

    [Diagnostic and Therapeutic Management of Episcleritis and Scleritis].

    Turgut F, Dingerkus V, Tappeiner C, Becker M

    Klinische Monatsblatter fur Augenheilkunde 2023; (240(5)):725-738 doi:10.1055/a-2022-0689.

    PMID: 36827997
  8. 8

    Case of isolated scleromalacia perforans with seropositivity for rheumatoid arthritis.

    Hajizadeh S, O'Donnell C, Dore A

    BMJ case reports 2024; (17(6)) doi:10.1136/bcr-2024-259863.

    PMID: 38925670
  9. 9

    Scleromalacia perforans as an early manifestation of late-onset rheumatoid arthritis: a case-based review.

    de Figueiredo LQ, de Andrade Lopes FO, Franco AS, et al.

    Rheumatology international 2024; (44(6)):1165-1173 doi:10.1007/s00296-023-05494-0.

    PMID: 37925382
  10. 10

    Scleromalacia perforans: a case report.

    Ghauri MI, Riaz SU, Husain A, et al.

    Journal of medical case reports 2018; (12(1)):155 doi:10.1186/s13256-018-1686-z.

    PMID: 29866188
  11. 11

    Digital Ischemia as a Rare Initial Presentation of Myeloperoxidase (MPO)-Anti-neutrophil Cytoplasmic Antibody (ANCA)-Positive Granulomatosis With Polyangiitis: A Case Report.

    Penaflor RK, Ong J, Phan M, Afroz S

    Cureus 2026; (18(4)):e107593 doi:10.7759/cureus.107593.

    PMID: 42038731
  12. 12

    ANCA-associated scleritis: impact of ANCA on presentation, response to therapy and outcome.

    Perray L, Nguyen Y, Clavel Refregiers G, et al.

    Rheumatology (Oxford, England) 2024; (63(2)):329-337 doi:10.1093/rheumatology/kead252.

    PMID: 37233203
  13. 13

    Chronic necrotizing sclerouveitis caused by Alternaria doliconidium.

    Menean M, Nicolini N, Cimino L, et al.

    European journal of ophthalmology 2026; (36(1)):NP16-NP18 doi:10.1177/11206721251369539.

    PMID: 40956900
  14. 14

    Necrotizing Scleritis: A Review.

    Dutta Majumder P, Agarwal S, Shah M, et al.

    Ocular immunology and inflammation 2024; (32(7)):1405-1419 doi:10.1080/09273948.2023.2206898.

    PMID: 37279404
  15. 15

    Infectious Scleritis - Clinical Characteristics, Causative Factors, and Treatment Outcomes in an Indian Population.

    Agarwal M, Radosavljevic A, Anand AR, et al.

    Ocular immunology and inflammation 2025; (33(2)):250-262 doi:10.1080/09273948.2024.2384534.

    PMID: 39115306

This page is for informational purposes only and does not constitute medical advice. An ophthalmologist and rheumatologist should guide testing and treatment for your specific situation.

Get notified when new evidence is published on scleromalacia perforans.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.